These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 20631270)
1. Incretin agents in type 2 diabetes. Ross SA; Ekoé JM Can Fam Physician; 2010 Jul; 56(7):639-48. PubMed ID: 20631270 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE; Lau J; Pittas AG JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601 [TBL] [Abstract][Full Text] [Related]
5. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell S Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796 [TBL] [Abstract][Full Text] [Related]
6. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Mikhail N Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986 [TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Garber AJ Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667 [TBL] [Abstract][Full Text] [Related]
8. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Blonde L; Montanya E Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266 [TBL] [Abstract][Full Text] [Related]
9. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Campbell RK; Cobble ME; Reid TS; Shomali ME J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236 [TBL] [Abstract][Full Text] [Related]
11. Combination pharmacotherapy with incretins: what works best and when? Over RK; Ratner RE Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584 [TBL] [Abstract][Full Text] [Related]
13. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
14. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy]. Lecube A; Bueno M; Suárez X Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462 [TBL] [Abstract][Full Text] [Related]
15. Incretins: their physiology and application in the treatment of diabetes mellitus. Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141 [TBL] [Abstract][Full Text] [Related]
16. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Siddiqui NI Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763 [TBL] [Abstract][Full Text] [Related]
17. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Verspohl EJ Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Blevins T Postgrad Med; 2010 Jan; 122(1):172-83. PubMed ID: 20107301 [TBL] [Abstract][Full Text] [Related]
20. Incretin physiology and its role in type 2 diabetes mellitus. Svec F J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]